SINUTAB CHILDRENS NASAL SPRAY ADVANCE

Indications

• Nasopharyngitis (common cold)
• Sinusitis (acute)
• Nasal congestion

Dosage

Children: For children aged 12-17 years, the recommended dosage is 2-3 drops of a 0.1% solution or 1 spray into each nostril 1-3 times a day as required, with a maximum duration of use of 7 days. Caution is advised for children under 12 years, as use is generally not recommended in younger children.

Adults: For adults, the usual dosage is 0.1% solution, administered as 1 spray into each nostril up to 3 times a day as required, with a maximum duration of use of 7 days.

Mechanism of action

Xylometazoline acts as an alpha-adrenergic agonist, stimulating alpha-1 adrenergic receptors on vascular smooth muscle, leading to vasoconstriction. This action reduces blood flow to the nasal mucosa, decreasing swelling and congestion. The onset of action is rapid, providing quick relief from nasal obstruction.

Pharmacodynamics

The pharmacodynamic effects of xylometazoline include significant vasoconstriction of nasal mucosa blood vessels, which leads to decreased nasal congestion. This effect can last for several hours, making it effective for acute conditions. However, prolonged use may lead to rebound congestion due to tolerance development.

Pharmacokinetics

Xylometazoline is administered intranasally, allowing for localized effects with minimal systemic absorption. Peak plasma concentrations are typically reached shortly after administration, although due to its local action, systemic effects are usually minimal. The metabolism and elimination pathways are not well characterized but are believed to involve hepatic metabolism and renal excretion.

Contra-indications

• Hypersensitivity to xylometazoline or any of its excipients
• Severe cardiovascular disease
• Closed-angle glaucoma
• Children under 6 years of age

Adverse effects

• Cardiovascular effects
• Headache
• Hypersensitivity reactions
• Nasal dryness
• Nausea
• Paresthesia
• Visual impairment
• Rebound congestion (rhinitis medicamentosa) with prolonged use
• Agitated psychosis, ataxia, hallucinations, and rare fatalities in infants and children under 6 years

Interactions

• Other sympathomimetics
• Vasoconstrictors

Precautions

• Use with caution in patients with diabetes mellitus
• Hypertension
• Hyperthyroidism
• Prolonged use should be avoided to prevent rebound congestion

Pregnancy

Manufacturer advises avoiding use during pregnancy due to insufficient data on safety.

Breast-feeding

Manufacturer advises caution as no information is available regarding the safety of xylometazoline during breastfeeding.

Storage

Store below 25°C. Do not freeze. Keep the container tightly closed.

Formulations

• {'name': 'Otrivine', 'type': 'Nasal spray', 'strength': '0.1%', 'volume': '15 ml'}
• {'name': 'Sudafed Sinus-Ease', 'type': 'Nasal drops', 'strength': '1 mg per 1 ml', 'volume': '10 ml'}

Indications

• Wound healing
• Skin moisturizing
• Epithelial protection
• Treatment of skin irritations
• Topical anti-inflammatory treatment

Dosage

Children: Refer to BNF for Children for specific dosing recommendations based on age and condition.

Adults: Topical application as needed, typically applied to the affected area 1 to 3 times daily.

Mechanism of action

Dexpanthenol is enzymatically converted to pantothenic acid, a precursor of coenzyme A. This coenzyme acts as a cofactor in numerous enzymatic reactions critical for protein metabolism, particularly in epithelial cells. Topically, dexpanthenol enhances fibroblast proliferation and accelerates re-epithelialization in wound healing. It also functions as a moisturizer and has anti-inflammatory properties. Additionally, it increases the availability of coenzyme A for synthesizing acetylcholine, which is essential for maintaining intestinal tone and peristalsis.

Pharmacodynamics

Dexpanthenol, through its active form pantothenic acid, contributes to various biochemical pathways, particularly those involving the synthesis of coenzyme A. This coenzyme facilitates the transfer of acetyl groups necessary for the synthesis of acetylcholine, a neurotransmitter that regulates parasympathetic nervous system functions, including gastrointestinal motility. Enhanced levels of acetylcholine promote normal intestinal functions, while a deficiency may lead to decreased peristalsis.

Pharmacokinetics

Dexpanthenol is readily absorbed when applied topically, and it is metabolized to pantothenic acid, which is then incorporated into various metabolic pathways. The pharmacokinetics of dexpanthenol, including its distribution, metabolism, and elimination, are influenced by the route of administration. Its efficacy in promoting wound healing is attributed to its ability to penetrate the skin and exert effects at the cellular level.

Pregnancy

Dexpanthenol is generally considered safe during pregnancy; however, its use should be based on a risk-benefit assessment by a healthcare provider.

Breast-feeding

Dexpanthenol is excreted in breast milk in small amounts. Caution is advised when administered to breastfeeding women, and its use should be evaluated in terms of potential benefits and risks.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Topical solution
• Cream
• Ointment

Indications

• Nasal congestion due to rhinosinusitis
• Allergic rhinitis
• Non-allergic rhinitis
• Common cold-related nasal congestion

Dosage

Adults: For adults, the typical dose is 0.1% to

Mechanism of action

Xylometazoline acts primarily as an agonist at α_2B-adrenergic receptors, with additional activity at α_1A-, α_2A-, α_2C-, α_1B-, and α_1D-adrenergic receptors. This agonistic action leads to vasoconstriction of the blood vessels in the nasal mucosa, decreasing nasal resistance during breathing and enhancing airflow. The drug's vasoconstrictive properties also contribute to symptomatic relief of associated conditions, such as earache and sore throat, which may arise from mouth breathing due to nasal congestion.

Pharmacodynamics

Xylometazoline is effective in reducing nasal congestion, with a median onset of relief approximately 1.7 minutes after administration and peak relief at around 30 minutes. Its vasoconstrictive effect can lead to rebound swelling and congestion if used long-term, with potential for rhinitis medicamentosa. The drug also exhibits antioxidant properties, which may protect against oxidative stress associated with inflammation in the nasal passages.

Pharmacokinetics

Xylometazoline is rapidly absorbed when administered nasally, although specific pharmacokinetic parameters such as half-life and bioavailability are not well-documented. Its effects are relatively short-lived, necessitating careful management of dosing to avoid rebound congestion. Regular use past the recommended duration can lead to diminished efficacy and increased risk of adverse effects.

Adverse effects

• Rebound congestion
• Nasal mucosa irritation
• Dryness of the nasal mucosa
• Headache
• Nausea

Interactions

• volatile halogenated anesthetics + xylometazoline: Unknown (additive effect)

Precautions

• Use with caution in patients with cardiovascular disease
• Use with caution in patients with hypertension
• Use with caution in patients with hyperthyroidism
• Avoid prolonged use to prevent rebound congestion

Pregnancy

Use during pregnancy only if clearly needed, as safety in pregnancy has not been established.

Breast-feeding

Use with caution, as it is not known whether xylometazoline is excreted in human milk.

Storage

Store below 30°C. Protect from light.

Formulations

• Nasal spray
• Nasal drops

Mechanism of action

Dexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol is enzymatically cleaved to form pantothenic acid, which is an essential component of Coenzyme A, which acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium. Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties. This alcohol ... is said to increase the amount of coenzyme A available for the synthesis of acetylcholine. Increased formation of acetylcholine is thought to increase peristalsis and intestinal tone. ... To test the functional effect of pantothenate on dermal fibroblasts, cells were cultured and in vitro proliferation tests were performed using a standardized scratch test procedure. For all three donors analyzed, a strong stimulatory effect of pantothenate at a concentration of 20 ug/mL on the proliferation of cultivated dermal fibroblasts was observed. To study the molecular mechanisms resulting in the proliferative effect of pantothenate, gene expression was analyzed in dermal fibroblasts cultivated with 20 ug/mL of pantothenate compared with untreated cells using the GeneChip Human Exon 1.0 ST Array. A number of significantly regulated genes were identified including genes coding for interleukin (IL)-6, IL-8, Id1, HMOX-1, HspB7, CYP1B1 and MARCH-II. Regulation of these genes was subsequently verified by quantitative real-time polymerase chain reaction analysis. Induction of HMOX-1 expression by pantothenol and pantothenic acid in dermal cells was confirmed on the protein level using immunoblots. Functional studies revealed the enhanced suppression of free radical formation in skin fibroblasts cultured with panthenol. In conclusion, these studies provided new insight in the molecular mechanisms linked to the stimulatory effect of pantothenate and panthenol on the proliferation of dermal fibroblasts. /Calcium pantotenate/ ... Pantothenic acid, pantothenol and other derivatives ... are precursors of CoA /that/ protect cells and whole organs against peroxidative damage by increasing the content of cell glutathione...

Pharmacodynamics

Pantothenic acid is a precursor of coenzyme A, which serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl groups. The final step in the synthesis of acetylcholine consists of the choline acetylase transfer of acetyl group from acetylcoenzyme A to choline. Acetylcholine is the neurohumoral transmitter in the parasympathetic system and as such maintains the normal functions of the intestine. Decrease in acetylcholine content would result in decreased peristalsis and in extreme cases adynamic ileus.

Mechanism of action

Nasal congestion is caused by various etiologies, such as rhinosinusitis and allergic or non-allergic rhinitis, leading to congestion of the venous sinusoids lining the nasal mucosa. Activation of α-adrenergic receptors leads to vasoconstriction of the blood vessels of the nasal mucosa and resumption of nasal airflow. As the most abundantly expressed in the human nasal mucosa, α_1A- and α_2B-adrenoceptors may play the most important role in vasoconstriction of the human nasal mucosa. Xylometazoline is a more selective agonist at α_2B-adrenoceptors, with affinity at α_1A-, α_2A-, α_2C-, α_1B-, and α_1D-adrenoceptors. Xylometazoline decreases nasal resistance during inspiration and expiration and increases the volume of nasal airflow. Compared to [oxymetazoline], another imidazoline nasal decongestant, xylometazoline had a slightly faster onset of action although they had a similar duration of action. In one study, subjects with nasal congestion reported relief of earache and sore throat in addition to nasal decongestion: it is speculated that oxymetazoline mediates this effect by causing vasoconstriction of the nasal mucosa that contains the venous sinuses and nasal decongestion allows breathing through the nose, providing relief from sore throat caused by mouth breathing that dries and irritates the throat.

Pharmacodynamics

Xylometazoline is a sympathomimetic agent that causes vasoconstriction of the nasal mucosa. In one study comprising subjects with nasal congestion associated with the common cold, the median time of onset of subjective relief of nasal congestion was about 1.7 minutes and the time of subjective peak relief of nasal congestion was 30 minutes. Previous studies reported rebound swelling, rebound nasal congestion, rhinitis medicamentosa, and shorter duration of decongestant effect from the long-term use of xylometazoline in healthy volunteers, suggesting that the drug is most effective if used temporarily. An early _in vitro_ study demonstrated xylometazoline to exert anti-oxidant actions, where it inhibited microsomal lipid peroxidation and mediated hydroxyl radical scavenging activity. This suggests that xylometazoline has a beneficial effect against oxidants, which play a role in tissue damage in inflammation.